Mangoceuticals, Inc. filed its Annual Report on Form 10-K with the SEC for the fiscal year ended December 31, 2025, disclosing share count, market value of non-affiliate holdings, and company registration details.
Key Highlights
- Shares outstanding: As of March 31, 2026, the company had 16,967,420 shares of Common Stock, $0.0001 par value, outstanding.
- Non-affiliate market value: The aggregate market value of Common Stock held by non-affiliates was approximately $14,725,437 as of June 30, 2025.
- Closing price used: The non-affiliate market value was based on a closing price of $1.52 per share on the Nasdaq Capital Market on June 30, 2025.
- Listing: The company's Common Stock trades on The NASDAQ Capital Market under the trading symbol MGRX.
- Company classification: The registrant identified itself as a non-accelerated filer, smaller reporting company, and emerging growth company.
- Shell company status: The registrant indicated it is not a shell company as defined in Rule 12b-2 of the Act.
Mangoceuticals Annual Filing Details for the Year Ended December 31, 2025
Mangoceuticals, Inc. (NASDAQ:MGRX), a Texas-incorporated company headquartered at 17130 Dallas Parkway, Suite 240, Dallas, Texas 75248, submitted its Annual Report on Form 10-K covering the fiscal year ended December 31, 2025. According to the filing, the company's Common Stock, $0.0001 par value per share, is registered on The NASDAQ Capital Market under the symbol MGRX. The registrant confirmed it has filed all reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months and has been subject to such filing requirements for the past 90 days.
The filing disclosed that as of June 30, 2025, the last day of the registrant's most recently completed second fiscal quarter, the aggregate market value of Common Stock held by non-affiliates was approximately $14,725,437. This figure was based on the closing price of $1.52 per share on the Nasdaq Capital Market on that date. The registrant noted that for purposes of this calculation, it assumed that directors, executive officers, and beneficial owners of 5% or more of its Common Stock are deemed affiliates, with the exception that 5% or greater stockholders were not deemed affiliates unless facts and circumstances indicate they exercise control over the company or unless they hold 10% or more of outstanding common stock.
As of March 31, 2026, the company reported 16,967,420 shares of its Common Stock outstanding. The registrant identified itself as a non-accelerated filer, smaller reporting company, and emerging growth company under Rule 12b-2 of the Exchange Act. The filing noted the company has not elected to use the extended transition period for complying with new or revised financial accounting standards. The filing also contains forward-looking statements, which the company characterized as subject to known and unknown risks, uncertainties, and other factors as described in its cautionary language and Risk Factors section.
What Was Disclosed
Mangoceuticals, Inc. filed its Form 10-K for fiscal year ended December 31, 2025, reporting 16,967,420 shares outstanding as of March 31, 2026, a non-affiliate market value of approximately $14,725,437 based on a $1.52 closing price on June 30, 2025, and its continued listing on NASDAQ:MGRX.




Please wait processing your request...